Proliferating cell nuclear antigen (PCNA) in high‐grade malignant fibrous histiocytoma: Prognostic value in 48 patients
Research output: Contribution to journal › Article
Grading based on histopathologic features is used to predict survival in soft‐tissue sarcoma. However, variations in clinical behavior between tumors of the same grade motivate a search for additional factors that correlate with prognosis. Proliferating cell nuclear antigen (PCNA) is expressed in proliferating cells during the G 1 S and G 2 ‐phases. To evaluate a prognostic implication of PCNA, the tumors of 48 patients with malignant fibrous histiocytomas (13 grade III, 35 grade IV) with a minimum follow‐up of 2 years were immunohistochemically studied. We used PC 10, a monoclonal antibody (MAb) directed against PCNA, which allows cell proliferation in formalin‐fixed, paraffinembedded tumor tissue to be evaluated. We appllied a semiquantitative PCNA grading scheme to all stained nuclei of an entire slide. The 3‐year metastasis‐free survival rate was 0.87 for patients in grade A (low PLNA rate), and 0.14 for patients in grade C (high PLNA). Our findings show that immunohistochemical evaluation of cell kinetics in soft‐tissue sarcomas by PCNA might be a useful adjunct to conventional tumor grading. © 1994 Wiley‐Liss, Inc.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||International Journal of Cancer|
|Publication status||Published - 1994 Nov 1|